Comparable stake leader
Sporos Bioventures LLC
SEC ownership of Tvardi Therapeutics, Inc.
Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001346830.
Disclosed value leader
Sporos Bioventures LLC
Comparable rows
50/50
Latest evidence
31 Mar 2026
- Public ticker
- TVRD on Nasdaq
- Parsed ownership sources
-
13D/G, 13F, and 3/4/5
Source: Parsed SEC ownership filingsUse: Compare filing families carefully
- Largest SEC-reported holder
-
Sporos Bioventures LLC
Ranking: Comparable ownership first, then disclosed value
- Comparable ownership rows
-
50 of 50
Meaning: Rows with safely comparable ownership %
- Latest 13D/G holder
-
Sporos Bioventures LLC
Source: Latest parsed Schedule 13D/G stake
- Latest parsed ownership date
-
31 Mar 2026
Freshness: Most recent filing date in this holder set
- Issuer CIK
- 0001346830
- Issuer location
- Sugar Land, TX
Ownership snapshot
CIK-linked ownership evidence from parsed SEC filings.
3 signals
Issuer
Names, identifiers, and filing context for this profile.
2 identity fields
Ownership snapshot
Top shareholders of Tvardi Therapeutics, Inc. (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
Sporos Bioventures LLC
Disclosed value leader
Sporos Bioventures LLC
Comparable rows
50/50
Latest evidence
31 Mar 2026
13D/G
13F
3/4/5
Lead comparable stake: 9%
13D/G row: Sporos Bioventures LLC
Showing 1-8 of 50 holder rows.
Quick read
Sporos Bioventures LLC leads the comparable SEC ownership view at 9%.
50 of 50 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens Sporos Bioventures LLC's linked filing trail.
Comparable ownership
Top 5
Sporos Bioventures LLC
9%
Solas Tvardi Sidecar LLC
8.1%
Slate Path Capital LP
7.5%
David J. Tweardy
7%
Ronald A. DePinho
4.5%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-8 of 50 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Sporos Bioventures LLC |
13D/G
|
9%
|
$19,544,812
837,636 shares
|
$0 | 15 Apr 2025 |
| Solas Tvardi Sidecar LLC |
13D/G
|
8.1%
|
$4,050,047
761,287 shares
|
$0 | 15 Apr 2025 |
| Slate Path Capital LP |
13D/G
13F
Company
|
7.5%
|
$19,257,627
704,118 shares
|
$0 | 30 Jun 2025 |
| David J. Tweardy |
13D/G
|
7%
|
$3,470,757
652,398 shares
|
$0 | 15 Apr 2025 |
| Ronald A. DePinho |
13D/G
|
4.5%
|
$1,939,164
426,190 shares
|
$0 | 31 Dec 2025 |
| Samuel D. Tweardy |
13D/G
|
3.4%
|
$7,365,343
315,658 shares
|
-$14,730,686 | 07 Jul 2025 |
| Vifor (International) Ltd |
3/4/5
13D/G
10%+ Owner
|
2.2%
from 13D/G
|
$9,024,059
7,396,770 shares
|
— | 20 Oct 2021 |
| BlackRock, Inc. |
13F
Company
|
4.1%
|
$1,234,077
388,075 shares
|
— | 31 Mar 2026 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Forms 3/4/5 flow
Insider trading overview
Insider buy and sell flow is broadly balanced over the last 12 months. No Buy or Sell transactions have been reported since 06 Aug 2025.
Buys
$0
Insiders: 0
Sells
$0
Insiders: 0
Net
$0
Shares: 0
Window
Last 12 months
4 rolling buckets
Buy value
Sell value
Shares: 0
Shares: 0
| Window (months) | Buy shares | Sell shares | Buy value | Sell value | Net value |
|---|---|---|---|---|---|
| 0-3 | 0 | 0 | $0 | $0 | $0 |
| 3-6 | 0 | 0 | $0 | $0 | $0 |
| 6-9 | 0 | 0 | $0 | $0 | $0 |
| 9-12 | 0 | 0 | $0 | $0 | $0 |
Reporting owners
Insider holders from Forms 3/4/5
Showing 1-20 of 28 reporting-owner rows connected to Tvardi Therapeutics, Inc.. Open a relationship link for the CIK-to-CIK filing trail.
Rows
28
Largest Forms 3/4/5 holder
CSL LTD
Net 12M change
$0
Latest report
09 Jun 2026
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| CSL LTD | 10%+ Owner | $9,024,059 | Mixed | 09 Aug 2022 | ||
| Vifor (International) Ltd | 10%+ Owner | $9,024,059 | Mixed | 20 Oct 2021 | ||
| Shaheen Wirk | Director | $2,225,966 | Mixed | 17 Apr 2025 | ||
| Wallace L. Hall Jr. | Director | $1,250,632 | Mixed | 09 Jun 2026 | ||
| Chalmers Derek T. | President & CEO, Director | $1,209,514 | Mixed | 07 Sep 2021 | ||
| Martin Vogelbaum | Director | $308,255 | Mixed | 04 Jun 2024 | ||
| Jeffrey L. Ives | Director | $148,864 | Mixed | 04 Jun 2024 | ||
| Lisa von Moltke | Director | $137,257 | Mixed | 04 Jun 2024 | ||
| Helen M. Boudreau | Director | $112,985 | Mixed | 04 Jun 2024 | ||
| Frederique Ph.D. Menzaghi | Chief Scientific Off,Svp R&D | $91,986 | Mixed | 01 Feb 2024 | ||
| Harrison M. Bains Jr. | Director | $70,074 | Mixed | 01 Jun 2023 | ||
| Christopher Posner | PRESIDENT AND CEO, Director | $62,268 | Filing P/S | 28 Feb 2025 | ||
| Thomas Charles Reilly | Chief Financial Officer | $46,129 | Mixed | 03 Mar 2022 | ||
| Joana Goncalves | Chief Medical Officer | $44,293 | Filing P/S | 05 Apr 2024 | ||
| Scott Terrillion | Sec'y; Chief Compliance & G.C. | $34,224 | Filing P/S | 28 Feb 2025 | ||
| Richard Makara | VP, Head of Accting;Controller | $16,571 | Mixed | 15 Jun 2022 | ||
| Ryan D. Maynard | Chief Financial Officer | $7,425 | Mixed | 08 Feb 2024 | ||
| Samuel D. Tweardy | 10%+ Owner | Mixed | 07 Jul 2025 | |||
| Michael S. Wyzga | Director | Mixed | 09 Jun 2026 | |||
| Sujal Shah | Director | Mixed | 09 Jun 2026 |
Recent insider transactions for Tvardi Therapeutics, Inc.
Showing up to 300 recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| Susan Ph.D. Shiff | TVRD | Stock Option (right to buy) | Award | 6,000 | 6,000 | 09 Jun 2026 | Direct | |||
| Cynthia Smith | TVRD | Stock Option (right to buy) | Award | 6,000 | 6,000 | 09 Jun 2026 | Direct | |||
| Sujal Shah | TVRD | Stock Option (right to buy) | Award | 6,000 | 6,000 | 09 Jun 2026 | Direct | |||
| Wallace L. Hall Jr. | TVRD | Stock Option (right to buy) | Award | 6,000 | 6,000 | 09 Jun 2026 | Direct | |||
| Michael S. Wyzga | TVRD | Stock Option (right to buy) | Award | 6,000 | 6,000 | 09 Jun 2026 | Direct | |||
| Avi Daniel Conn | TVRD | Employee Stock Option (right to buy) | Award | 45,000 | 45,000 | 29 Jan 2026 | Direct | |||
| Stephen Paul O'Brien | TVRD | Employee Stock Option (right to buy) | Award | 15,000 | 15,000 | 29 Jan 2026 | Direct | |||
| Imran Nizamudin Alibhai | TVRD | Employee Stock Option (right to buy) | Award | 115,000 | 115,000 | 29 Jan 2026 | Direct | |||
| John Saewook M.d. Kauh | TVRD | Employee Stock Option (right to buy) | Award | 45,000 | 45,000 | 29 Jan 2026 | Direct | |||
| Stephen Paul O'Brien | TVRD | Employee Stock Option (right to buy) | Award | 4,000 | 4,000 | 16 Dec 2025 | Direct | |||
| John Saewook M.d. Kauh | TVRD | Employee Stock Option (right to buy) | Award | 17,500 | 17,500 | 16 Dec 2025 | Direct | |||
| Avi Daniel Conn | TVRD | Employee Stock Option (right to buy) | Award | 17,500 | 17,500 | 16 Dec 2025 | Direct | |||
| Imran Nizamudin Alibhai | TVRD | Employee Stock Option (right to buy) | Award | 47,500 | 47,500 | 16 Dec 2025 | Direct |
* marks a reported price that did not pass the local price check.